Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heron Therapeutics ( (HRTX) ) has issued an announcement.
On October 13, 2025, Heron Therapeutics held a Special Stockholders’ Meeting where stockholders approved two proposals related to the issuance of common stock. The approvals, in accordance with Nasdaq Listing Rule 5635(d), allow for the issuance of shares exceeding 19.99% of the company’s outstanding stock under certain future circumstances, linked to the conversion of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
The most recent analyst rating on (HRTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Heron Therapeutics stock, see the HRTX Stock Forecast page.
Spark’s Take on HRTX Stock
According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.
Heron Therapeutics faces significant financial challenges, including high leverage and negative equity, which weigh heavily on its overall score. While the company has shown strong revenue growth and strategic progress, these are overshadowed by ongoing profitability issues and a negative P/E ratio. Technical indicators suggest neutral momentum, providing little support for a higher score.
To see Spark’s full report on HRTX stock, click here.
More about Heron Therapeutics
Heron Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of therapeutic products. The company primarily targets pain management and cancer care markets with its innovative drug delivery systems.
Average Trading Volume: 1,719,815
Technical Sentiment Signal: Sell
Current Market Cap: $238.3M
See more insights into HRTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “More Hopeful than Real”: Is a Bidding War Brewing for Warner Bros. Discovery Stock (NASDAQ:WBD)?
- “Didn’t Develop the Way Automakers Thought.” Ford Notches Up, Reconsidering the EV Market
- “Our Focus is Increasingly…on Inference”: Intel Stock (NASDAQ:INTC) Jumps With Crescent Island Testing Next Year